Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Consolidated Net Income: 2016-2024

Historic Consolidated Net Income for Akebia Therapeutics (AKBA) over the last 9 years, with Dec 2024 value amounting to -$69.4 million.

  • Akebia Therapeutics' Consolidated Net Income rose 102.69% to $540,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.9 million, marking a year-over-year increase of 65.42%. This contributed to the annual value of -$69.4 million for FY2024, which is 33.67% down from last year.
  • As of FY2024, Akebia Therapeutics' Consolidated Net Income stood at -$69.4 million, which was down 33.67% from -$51.9 million recorded in FY2023.
  • In the past 5 years, Akebia Therapeutics' Consolidated Net Income registered a high of -$51.9 million during FY2023, and its lowest value of -$384.8 million during FY2020.
  • Its 3-year average for Consolidated Net Income is -$71.9 million, with a median of -$69.4 million in 2024.
  • In the last 5 years, Akebia Therapeutics' Consolidated Net Income plummeted by 37.61% in 2020 and then skyrocketed by 66.59% in 2022.
  • Over the past 5 years, Akebia Therapeutics' Consolidated Net Income (Yearly) stood at -$384.8 million in 2020, then climbed by 26.72% to -$282.0 million in 2021, then skyrocketed by 66.59% to -$94.2 million in 2022, then spiked by 44.89% to -$51.9 million in 2023, then crashed by 33.67% to -$69.4 million in 2024.